Effect of linezolid on inflammatory factors and T lymphocyte levels in patients with severe tuberculosis
10.3760/cma.j.issn.1008-6706.2019.17.012
- VernacularTitle: 利奈唑胺对重症结核病患者炎性因子、T淋巴细胞水平的影响
- Author:
Yangrong CAO
1
Author Information
1. Department of Tuberculosis, Jinhua Guangfu Hospital, Jinhua, Zhejiang 321000, China
- Publication Type:Journal Article
- Keywords:
Tuberculosis;
Antitubercular agents;
Immunity, cellular;
Liver function tests;
Inflammation mediators;
Interleukins;
Tumor necrosis factor-alpha;
Linezolid
- From:
Chinese Journal of Primary Medicine and Pharmacy
2019;26(17):2097-2100
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To observe the effects of linezolid on the levels of inflammatory factors and T lymphocytes in patients with severe tuberculosis.
Methods:Sixty patients with severe tuberculosis treated in Jinhua Guangfu Hospital from April 2016 to November 2017 were selected and divided into control group(n=30) and observation group(n=30) according to different treatment options.The control group was treated with personalized anti-tuberculosis regimen.The observation group was treated with linezolid on the basis of the control group, and both two groups were treated for 9 months.The changes of interleukin-1(IL-1), tumor necrosis factor alpha(TNF-α), IL-6, IL-10 and CD3+, CD4+, CD8+ and CD4+/CD8+ were observed before and after treatment.The incidence of liver injury, thrombocytopenia, myelosuppression, nausea and vomiting, diarrhea were observed.
Results:Before treatment, there were no statistically significant differences in IL-1, TNF-α, IL-6, IL-10, CD3+, CD4+, CD8+, CD4+/CD8+ between the two groups(all P>0.05). At 9 months after treatment, the levels of IL-1, TNF-α, IL-6 and IL-10 in the control group were (10.94±1.31)ng/L, (3.03±0.49)ng/L, (183.43±13.24)ng/L, (134.93±34.51)ng/L, respectively, which in the observation group were (6.89±1.29)ng/L, (2.49±0.45)ng/L, (129.48±10.74)ng/L, (189.35±43.27)ng/L, respectively, the differences between the two groups were statistically significant(t=12.195, 11.214, 8.414, 11.291, all P<0.05). The CD3+, CD4+, CD8+, CD4+/CD8+ in the control group were (47.61±7.16)%, (15.49±6.64)%, (20.58±5.61)%, (0.79±0.19) , respectively, which in the observation group were (65.46±8.31)%, (30.23±7.85)%, (34.59±7.41)%, (0.87±0.24) , respectively, the differences between the two groups were statistically significant(t=10.497, 7.865, 12.128, 10.291, all P<0.05). There were no statistically significant differences in the incidence of liver function impairment, thrombocytopenia, myelosuppression, nausea and vomiting, and diarrhea between the two groups(all P>0.05).
Conclusion:Linezolid in the treatment of severe tuberculosis can reduce the level of inflammatory factors, improve the cellular immune level of patients, and has a lower incidence of adverse effects.
